EN DE
Watch Greenyn Biotechnology Co., Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Greenyn Biotechnology Co., Ltd (6846) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Greenyn Biotechnology Co., Ltd stock TWD 55.58, price TWD 49.00, upside +13.4%, quality 42 out of 100. Rating: undervalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW

GB Greenyn Biotechnology Co., Ltd logo Thin data Nov 9, 2026

Greenyn Biotechnology Co., Ltd

6846 · TWO
Speculative

The stock costs 12% less than our calculation considers fair.

Fair value 55.58 TWD · Undervalued
Solidly profitable · 15.9% net margin (FY2025)
Ranks above peers (8/10)
Quality 42/100
Expensive Growth (revenue 3y +9.1 %/yr in TWD)
Moderate debt
Moderate moat 61/100 · thin data
Negative free cash flow
Thin data
Watch Greenyn Biotechnology Co., Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

101.72 TWD 49.00 TWD Fair Value 55.58 TWD Apr 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

55‑month range 49.00 TWD – 101.72 TWD · fair‑value band 36.56 TWD – 79.59 TWD · the 49.00 TWD price screens below the 55.58 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Greenyn Biotechnology Co. in your weekly email

Every Wednesday you see whether Greenyn Biotechnology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Greenyn Biotechnology Co., Ltd, a dietary supplement company, develops, manufactures, and sells health products in Taiwan and internationally.

Show moreShow less

The company offers proprietary ingredients, such as Insumate, a bitter melon extract; Antromax, an antrodia cinnamomea; and Zymologist 101 Phyto fermented drink.

It also provides functional formulas for youth and beauty series, digestive health series, brain health series, body regulation series, throat moistening series, hair care series, clear eye series, colorful lifestyle series, joint health series, nutritional supplement series, energy supplement series, immune modulation series, low burden series, sleep aid series, body curve series, circulation series, man power series, women's intimate health series, and mature woman series.

In addition, the company offers customization, ODM, dosage, and application services. Greenyn Biotechnology Co., Ltd was founded in 2012 and is based in Taichung, Taiwan.

Stock analysis

Greenyn Biotechnology Co., Ltd (6846) currently trades at 49.00 TWD, while our model-based Fair Value estimate is 55.58 TWD, implying the stock looks roughly 12% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 114.73 TWD per share, and 11 of the 16 models we run sit above the 49.00 TWD price.

Bear case: the Asset-Based group reads lowest at 13.07 TWD, and 5 of the 16 models stay below the price. Data coverage for this calculation is low.

Scenario range: 36.56 TWD (bear) to 79.59 TWD (bull), the price of 49.00 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Greenyn Biotechnology Co., Ltd reported revenue of 915M TWD in FY2025 versus 694M TWD in FY2021, a compound +7.2%/yr. Reported net income was 146M TWD in FY2025, compounding +2.3%/yr from FY2021.

Key figures

Market cap 1.3B TWD (≈ $40.3M) Micro · P/E ratio 12.2 · P/S ratio 1.93 · EPS (TTM) 4.03 TWD · Dividend yield 6.2% · Net margin 15.9% · Return on assets (EBIT) 15.6% (5-year average) · Free cash flow −236M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 61 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 13%, 6846 screens cheaper than that median.

Fair Value models

Bear 36.56 TWD Fair Value 55.58 TWD Bull 79.59 TWD
Price 49.00 TWD · Upside +13.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (3.46 TWD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income 34.74 TWD 41.76 TWD 55.19 TWD 73
EPV 44.25 TWD 51.08 TWD 56.86 TWD 71
ROIC Compounder 45.92 TWD 57.02 TWD 69.98 TWD 69
All 16 models by family
Earnings-Based
Graham-Dodd 36.56 TWD 114.08 TWD 151.75 TWD 62
Lynch FV 24.84 TWD 35.48 TWD 46.13 TWD 58
PEG = 1.0 24.84 TWD 35.48 TWD 46.13 TWD 55
EPV 44.25 TWD 51.08 TWD 56.86 TWD 71
Dividend Discount
Gordon GGM 29.52 TWD 55.58 TWD 79.59 TWD 64
DDM Multi-Stage 29.52 TWD 46.87 TWD 59.08 TWD 64
Multiples
P/E Multiple 88.71 TWD 118.28 TWD 147.85 TWD 63
P/S Multiple 68.55 TWD 91.40 TWD 114.25 TWD 58
P/B Multiple 122.02 TWD 162.70 TWD 203.37 TWD 55
EV/EBIT 86.37 TWD 116.02 TWD 145.67 TWD 66
EV/EBITDA 84.43 TWD 113.43 TWD 142.43 TWD 67
EV/Revenue 60.91 TWD 88.12 TWD 115.32 TWD 53
Asset-Based
NCAV (Graham) 8.63 TWD 13.07 TWD 16.34 TWD 54
Economic Profit
Residual Income 34.74 TWD 41.76 TWD 55.19 TWD 73
ROIC Compounder 45.92 TWD 57.02 TWD 69.98 TWD 69
Growth Earnings
Growth-Adj P/E 73.06 TWD 104.37 TWD 135.68 TWD 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 48
How much profit the company makes from its sales and capital
Quality Growth 29
Are margins and returns getting better?
Cashflow 26
Do the profits arrive as real cash?
Financial strength 80
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 86
How calm the share price moves, does not count
Price momentum 17
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 63
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 41/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+4.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.1%
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+6.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.2%
Dividend (yield on the price)6.2%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 21%

Watch 6846, get fair value alerts →

Compare Greenyn Biotechnology Co., Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 7/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 42 · Below median
Fair Value upside +13.4% · Top 25%
Profitability
Return on assets 6.9% · Top 25%
Net margin (12 months) 15.9% · Above median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Dividend yield (12 months) 6.2% · Top 25%
Balance sheet
Debt / equity 0.88× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 12.2× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)51 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)56 · sector 97
DIVIDEND (yield)100 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 6846
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 6846
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 6846
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 6846
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 6846
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 6846
argenx SE ARGX $927.21 $908.40 −2% vs 6846
CSL Limited CSL A$200.77 A$183.04 −9% vs 6846
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 6846
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 6846

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Greenyn Biotechnology Co., Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Greenyn Biotechnology Co., Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6846

Frequently asked questions

Is Greenyn Biotechnology Co., Ltd (6846) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 55.58 TWD versus a price of 49.00 TWD, about +13% upside (undervalued).
What is the fair value of 6846?
Our model-based fair value for Greenyn Biotechnology Co., Ltd is 55.58 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 49.00 TWD.
What is the quality score of 6846?
Greenyn Biotechnology Co., Ltd has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Greenyn Biotechnology Co., Ltd (6846)?
Our model-based price target is the fair value of 55.58 TWD (as of Nov 9, 2026) from 16 valuation models. Cautious scenario 36.56 TWD, optimistic scenario 79.59 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Greenyn Biotechnology Co., Ltd stock forecast for 2026?
Our models put fair value at 55.58 TWD, about +13% upside versus a price of 49.00 TWD (undervalued). Cautious scenario 36.56 TWD, optimistic scenario 79.59 TWD. The calculation is refreshed regularly with new filings.
Does Greenyn Biotechnology Co., Ltd pay a dividend?
Greenyn Biotechnology Co., Ltd currently shows a dividend yield of 6.16% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Greenyn Biotechnology Co., Ltd (6846)?
Greenyn Biotechnology Co., Ltd has a dividend yield of 6.2%.
What is the intrinsic value of Greenyn Biotechnology Co., Ltd (6846)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Greenyn Biotechnology Co., Ltd it is 55.58 TWD per share (as of Nov 9, 2026), against a price of 49.00 TWD. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Greenyn Biotechnology Co., Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 6846 trades below its calculated fair value: price 49.00 TWD, fair value 55.58 TWD, a gap of about +13% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6846?
No. The price is what the market pays today (49.00 TWD); the fair value is what the company's own numbers justify (55.58 TWD). For Greenyn Biotechnology Co., Ltd the two are 6.58 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Greenyn Biotechnology Co., Ltd worth?
The market values Greenyn Biotechnology Co., Ltd at about 1.3B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 49.00 TWD; our models calculate a fair value of 55.58 TWD per share.
What do the bullish and bearish scenarios say about 6846?
Our models span a range for Greenyn Biotechnology Co., Ltd: cautious scenario 36.56 TWD, base 55.58 TWD, optimistic 79.59 TWD per share (as of Nov 9, 2026, price 49.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6846?
Greenyn Biotechnology Co., Ltd trades at a price-to-earnings ratio of 12.2 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 55.58 TWD is built from several models across several years.
How solid is the balance sheet of Greenyn Biotechnology Co., Ltd (6846)?
Balance-sheet figures for Greenyn Biotechnology Co., Ltd (as of Nov 9, 2026): debt of 0.88 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 6846 from its 52-week high?
Greenyn Biotechnology Co., Ltd trades at 49.00 TWD, about 33% below its 52-week high of 73.31 TWD and at the low of 49.00 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 55.58 TWD is for.
Which stocks are comparable to Greenyn Biotechnology Co., Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Greenyn Biotechnology Co., Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 49.00 TWD, calculated fair value 55.58 TWD (+13%), Quality Score 42/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6846 calculated?
We run Greenyn Biotechnology Co., Ltd through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 55.58 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Greenyn Biotechnology Co., Ltd currently trades 12% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Greenyn Biotechnology Co., Ltd (6846)?
The closing price on Nov 6, 2026 was 49.00 TWD. Our model-based fair value is 55.58 TWD, about +13% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Greenyn Biotechnology Co., Ltd right now?
A fairly wide model range (36.56 TWD to 79.59 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Greenyn Biotechnology Co., Ltd

How large is the market capitalisation of Greenyn Biotechnology Co., Ltd (6846)?
The market capitalisation of Greenyn Biotechnology Co., Ltd is 1.3B TWD (≈ $40.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Greenyn Biotechnology Co., Ltd (6846)?
The price-to-sales ratio of Greenyn Biotechnology Co., Ltd is 1.93 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Greenyn Biotechnology Co., Ltd (6846)?
Earnings per share at Greenyn Biotechnology Co., Ltd are 4.03 TWD (price ÷ EPS = P/E 12.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Greenyn Biotechnology Co., Ltd (6846)?
The dividend yield of Greenyn Biotechnology Co., Ltd is 6.2% (payout 74.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Greenyn Biotechnology Co., Ltd (6846)?
The net margin of Greenyn Biotechnology Co., Ltd is 15.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Greenyn Biotechnology Co., Ltd (6846)?
On an EBIT basis the return on assets of Greenyn Biotechnology Co., Ltd is 15.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Greenyn Biotechnology Co., Ltd (6846) generate?
The free cash flow of Greenyn Biotechnology Co., Ltd is −236M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Greenyn Biotechnology Co., Ltd (6846) carry?
The net debt of Greenyn Biotechnology Co., Ltd is 69.5M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Greenyn Biotechnology Co., Ltd in the live analysis

One click puts Greenyn Biotechnology Co., Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.